HARP News and Press, Harpoon Therapeutics Inc. From 01/27/20

Insider buying decreased significantly last week with insiders purchasing $11.65 million of stock compared to $48.31 million in the week prior. Selling also decreased with insiders selling $569.34 million of stock last week compared to $714.05 million in the week prior. Sell/Buy Ratio: The...

Gainers: Iterum Therapeutics (NASDAQ: ITRM ) +121% . More news on: Iterum Therapeutics plc, Pintec Technology Holdings Limited, PDS Biotechnology Corporation, Stocks on the move, Read more ...

The following slide deck was published by Harpoon Therapeutics, Inc. in conjunction with this Read more ...

The healthcare sector seems to be waking up over the past several weeks. Political uncertainty has been hurting healthcare stocks throughout the past year, but this uncertainty seems to be dissipating as the Presidential election approaches, which is being a major tailwind for the healthcare ...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Watch t...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate i...

Harpoon grants AbbVie option to license worldwide rights to HPN217 (BCMA), a TriTAC for the treatment of multiple myeloma planned for IND filing this year Expanded TriTAC discovery collaboration includes up to six additional targets selected by AbbVie Two agreements provide for...

The following slide deck was published by Harpoon Therapeutics, Inc. in conjunction with this Read more ...

Arvinas (NASDAQ: ARVN ) initiated with Buy rating and $35 (23% upside) price target at Roth Capital. More news on: Arvinas, Inc., Bicycle Therapeutics plc, Harpoon Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...